157 related articles for article (PubMed ID: 20553997)
1. Neurofibromatosis type 2: molecular and clinical analyses in Argentine sporadic and familial cases.
Ferrer M; Schulze A; Gonzalez S; Ferreiro V; Ciavarelli P; Otero J; Giliberto F; Basso A; Szijan I
Neurosci Lett; 2010 Aug; 480(1):49-54. PubMed ID: 20553997
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the NF2 gene in sporadic meningiomas by denaturing high-performance liquid chromatography.
Kim JH; Kim IS; Kwon SY; Jang BC; Suh SI; Shin DH; Jeon CH; Son EI; Kim SP
Int J Mol Med; 2006 Jul; 18(1):27-32. PubMed ID: 16786152
[TBL] [Abstract][Full Text] [Related]
3. [Neurofibromatosis type 2 (NF2)].
Araki N; Takeshima H; Saya H
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1427-31. PubMed ID: 9309136
[TBL] [Abstract][Full Text] [Related]
4. NF2: the wizardry of merlin.
Xiao GH; Chernoff J; Testa JR
Genes Chromosomes Cancer; 2003 Dec; 38(4):389-99. PubMed ID: 14566860
[TBL] [Abstract][Full Text] [Related]
5. Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function.
Kley N; Whaley J; Seizinger BR
Glia; 1995 Nov; 15(3):297-307. PubMed ID: 8586465
[TBL] [Abstract][Full Text] [Related]
6. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
[TBL] [Abstract][Full Text] [Related]
7. [Development and establishment of a yeast-based stop codon assay for detection of NF2 gene premature-terminating mutations].
Kobayashi H
Hokkaido Igaku Zasshi; 1999 Sep; 74(5):377-86. PubMed ID: 10495852
[TBL] [Abstract][Full Text] [Related]
8. The tumour suppressor protein NF2/merlin: the puzzle continues.
Hovens CM; Kaye AH
J Clin Neurosci; 2001 Jan; 8(1):4-7. PubMed ID: 11148074
[TBL] [Abstract][Full Text] [Related]
9. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset.
Smith MJ; Higgs JE; Bowers NL; Halliday D; Paterson J; Gillespie J; Huson SM; Freeman SR; Lloyd S; Rutherford SA; King AT; Wallace AJ; Ramsden RT; Evans DG
J Med Genet; 2011 Apr; 48(4):261-5. PubMed ID: 21278391
[TBL] [Abstract][Full Text] [Related]
10. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
Kley N; Seizinger BR
Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
[TBL] [Abstract][Full Text] [Related]
11. Magic but treatable? Tumours due to loss of merlin.
Hanemann CO
Brain; 2008 Mar; 131(Pt 3):606-15. PubMed ID: 17940085
[TBL] [Abstract][Full Text] [Related]
12. Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas.
Singh PK; Gutmann DH; Fuller CE; Newsham IF; Perry A
Mod Pathol; 2002 May; 15(5):526-31. PubMed ID: 12011257
[TBL] [Abstract][Full Text] [Related]
13. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
14. Tight association of loss of merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas.
Ueki K; Wen-Bin C; Narita Y; Asai A; Kirino T
Cancer Res; 1999 Dec; 59(23):5995-8. PubMed ID: 10606247
[TBL] [Abstract][Full Text] [Related]
15. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants.
Wellenreuther R; Waha A; Vogel Y; Lenartz D; Schramm J; Wiestler OD; von Deimling A
Lab Invest; 1997 Dec; 77(6):601-6. PubMed ID: 9426397
[TBL] [Abstract][Full Text] [Related]
17. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function.
Surace EI; Haipek CA; Gutmann DH
Oncogene; 2004 Jan; 23(2):580-7. PubMed ID: 14724586
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations in the neurofibromatosis type 2 gene and its protein rarely occurring in meningothelial meningiomas.
Evans JJ; Jeun SS; Lee JH; Harwalkar JA; Shoshan Y; Cowell JK; Golubic M
J Neurosurg; 2001 Jan; 94(1):111-7. PubMed ID: 11147878
[TBL] [Abstract][Full Text] [Related]
19. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients.
Ruggieri M; Iannetti P; Polizzi A; La Mantia I; Spalice A; Giliberto O; Platania N; Gabriele AL; Albanese V; Pavone L
Neuropediatrics; 2005 Feb; 36(1):21-34. PubMed ID: 15776319
[TBL] [Abstract][Full Text] [Related]
20. Lack of genetic and epigenetic changes in meningiomas without NF2 loss.
van Tilborg AA; Morolli B; Giphart-Gassler M; de Vries A; van Geenen DA; Lurkin I; Kros JM; Zwarthoff EC
J Pathol; 2006 Mar; 208(4):564-73. PubMed ID: 16353169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
